Abstract:Persons with germline variants in the tumor suppressor gene phosphatase and tensin homolog, PTEN , are molecularly diagnosed with PTEN hamartoma tumor syndrome (PHTS). PHTS confers high risks of specific malignancies, and up to 23% of the patients are diagnosed with autism spectrum disorder (ASD) and/or developmental delay (DD). The accurate prediction of these two seemingly disparate phenotypes (cancer vs . ASD/DD) for PHTS at the individual level remains elusive despite the available statistical prevalence of specific phenotypes of the syndrome at the population level. The pleiotropy of the syndrome may, in part, be due to the alterations of the key multi-functions of PTEN. Maintenance of genome integrity is one of the key biological functions of PTEN, but no integrative studies have been conducted to quantify the DNA damage response (DDR) in individuals with PHTS and to relate to phenotypes and genotypes. In this study, we used 43 PHTS patient-derived lymphoblastoid cell lines (LCLs) to investigate the associations between DDR and PTEN genotypes and/or clinical phenotypes ASD/DD vs . cancer. The dynamics of DDR of γ-irradiated LCLs were analyzed using the exponential decay mathematical model to fit temporal changes in γH2AX levels which report the degree of DNA damage. We found that PTEN nonsense variants are associated with less efficient DNA damage repair ability resulting in higher DNA damage levels at 24 hours after irradiation compared to PTEN missense variants. Regarding PHTS phenotypes, LCLs from PHTS individuals with ASD/DD showed faster DNA damage repairing rate than those from patients without ASD/DD or cancer. We also applied the reaction-diffusion partial differential equation (PDE) mathematical model, a tumor cell growth model with a DNA damage term, to accurately describe the DDR process in the LCLs. For each LCL, we can derive parameters of the PDE. Then we averaged the numerical results by PHTS phenotypes. By performing simple subtraction of two subgroup average results, we found that PHTS-ASD/DD is associated with higher live cell density at lower DNA damage level but lower cell density level at higher DNA damage level compared to LCLs from individuals with PHTS-cancer and PHTS-neither. PTEN is a shared risk gene for both cancer and autism spectrum disorder (ASD) and/or developmental delay (DD). Accurate prediction of the clinical phenotypes of each PTEN hamartoma tumor syndrome (PHTS) individual is still not feasible, though population-level risks of ASD/DD and specific component cancers, including breast cancer and thyroid cancer, have been estimated within PHTS cohorts. In this study we provide insights that PHTS-ASD/DD is associated with faster DNA damage repair rate (half-life of phosphorylated H2A histone family member X, γH2AX, signal over time) and LCLs derived from individuals with PHTS-cancer are related with susceptibility to γ irradiation. PHTS-ASD/DD also showed a higher live cell density when DNA damage was at a low level, and lower live cell density at high DNA damage levels compared to the other PHTS phenotypes. Finally, we provide an innovative way to describe DNA damage response (DDR) in a quantitative and integrative fashion, which is applicable to any type of cells.

Quantitative evaluation of DNA damage repair dynamics to elucidate predictors of autism vs . cancer in individuals with germline PTEN variants

Distinct metabolic profiles associated with autism spectrum disorder versus cancer in individuals with germline PTEN mutations

The mitochondrial genome as a modifier of autism versus cancer phenotypes in PTEN hamartoma tumor syndrome

Developmental and behavioral phenotypes of pediatric patients with PTEN hamartoma tumor syndrome

Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants

A Bi-Institutional Study of Gastrointestinal and Hepatic Manifestations in Children With PTEN Hamartoma Tumor Syndrome

Clinical, histological and receptor profiles of invasive breast cancer and ductal carcinoma in situ in females with germline pathogenic variants in PTEN and implications for germline testing

Exploring the neurological features of individuals with germline PTEN variants: A multicenter study

Diagnosis of PTEN mosaicism: the relevance of additional tumor DNA sequencing. A case report and review of the literature

PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage

Behavioural, developmental and psychological characteristics in children with germline PTEN mutations: a carer report study

Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease

Distinct Alterations in Tricarboxylic Acid Cycle Metabolites Associate with Cancer and Autism Phenotypes in Cowden Syndrome and Bannayan-Riley-Ruvalcaba Syndrome

Pathologists' integration of prior biopsies of women with germline PTEN mutations may expedite the identification of this rare cancer predisposition syndrome

Mutation-Positive and Mutation-Negative Patients with Cowden and Bannayan-Riley-Ruvalcaba Syndromes Associated with Distinct 10q Haplotypes

PTEN Hamartoma Tumor Syndrome: A Clinical Overview

Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study

Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations

Abstract 979: Cell-free DNA fragmentomics and second malignant neoplasm risk in patients with PTEN hamartoma tumor syndrome

Cerebellar phenotypes in germline PTEN mutation carriers

Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review